Publication Name	World Journal of Clinical Cases
Manuscript ID	72779
Country	United States

Received	2021-10-27 16:12
Peer-Review Started	2021-10-27 16:14
To Make the First Decision
Return for Revision	2021-12-13 03:54
Revised	2022-01-20 03:48
Second Decision	2022-03-25 06:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-03-26 21:48
Articles in Press	2022-03-26 21:48
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-04-19 09:13
Publish the Manuscript Online	2022-05-13 08:46

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Opinion Review
Article Title	Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
Manuscript Source	Invited Manuscript
All Author List	Hala Najeeb, Farah Yasmin and Salim Surani
ORCID	Author(s) ORCID Number Hala Najeeb http://orcid.org/0000-0001-7075-4674 Farah Yasmin http://orcid.org/0000-0002-5264-6140 Salim Surani http://orcid.org/0000-0001-7105-4266
Funding Agency and Grant Number
Corresponding Author	Salim Surani, FACP, FCCP, MD, MSc, Doctor, Professor, Department of Medicine, Texas A&M University, 400 Bizzell St, College Station, TX 77843, United States. srsurani@hotmail.com
Key Words	Inflammatory bowel disease; Biosimilars; Anti-tumor necrosis factor; Infliximab; Adalimumab; Ulcerative colitis; Chrons disease
Core Tip	There is limited evidence on the safety and use of biosimilars other than Infliximab. This review explores the role of biosimilars in an era of anti-tumor necrosis factor-α drug as a treatment option for inflammatory bowel disease. The approval of biosimilars by the Food and Drug Administration or European Medicines Agency based on their similarity and functionality to the reference product has raised concerns regarding its efficacy. Many remain hesitant in recommending biosimilars as a viable treatment option, despite its promise of reducing long-term costs. This originates from the lack of clinical trials of biosimilars. Although no serious adverse events have been reported with biosimilars, conclusions cannot be drawn without sufficient empirical evidence.
Publish Date	2022-05-13 08:46
Citation	Najeeb H, Yasmin F, Surani S. Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients. World J Clin Cases 2022; 10(14): 4327-4333
URL	https://www.wjgnet.com/2307-8960/full/v10/i14/4327.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i14.4327

Full Article (PDF)	WJCC-10-4327.pdf
Full Article (Word)	WJCC-10-4327.docx
Manuscript File	72779_Auto_Edited.docx
Answering Reviewers	72779-Answering reviewers.pdf
Audio Core Tip	72779-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	72779-Conflict-of-interest statement.pdf
Copyright License Agreement	72779-Copyright license agreement.pdf
Peer-review Report	72779-Peer-review(s).pdf
Scientific Misconduct Check	72779-Bing-Chen YL-2.png
Scientific Editor Work List	72779-Scientific editor work list.pdf